Muhammad Akhtar, MD
Neurology · Chillicothe, OHNPI 1740266022
Payments from drug & device makers
Across 238 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Neurocrine Biosciences, Inc.$304
- SK Life Science, Inc.$263
- Supernus Pharmaceuticals, Inc.$223
- UCB, Inc.$182
- Lilly USA, LLC$157
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$70016%
- Food & beverage$3,69984%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,636 |
| Neurocrine Biosciences, Inc. | 20 | $304 |
| SK Life Science, Inc. | 15 | $263 |
| Supernus Pharmaceuticals, Inc. | 17 | $223 |
| UCB, Inc. | 11 | $182 |
| Lilly USA, LLC | 11 | $157 |
| MDD US Operations, LLC | 6 | $152 |
| Teva Pharmaceuticals USA, Inc. | 9 | $148 |
| Pfizer | 9 | $147 |
| EMD Serono, Inc. | 2 | $131 |
| Biogen | 7 | $119 |
| Eisai Inc. | 7 | $114 |
| Acadia Pharmaceuticals Inc | 8 | $113 |
| Amgen | 7 | $93 |
| Ipsen Biopharmaceuticals, Inc | 5 | $92 |
| Sunovion Pharmaceuticals Inc. | 7 | $88 |
| Amneal Pharmaceuticals LLC | 6 | $87 |
| Novartis | 5 | $76 |
| Abbott | 3 | $46 |
| AstraZeneca(2 entities) | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Aucta Pharmaceuticals, Inc. | 2 | $20 |
| Bristol Myers Squibb | 1 | $17 |
| Sanofi | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Adamas Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,415 in reported general payments places this provider in the 60th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 12 | $513,682 |
| AustedoDeutetrabenazine | 27 | $148,716 |
| Nurtec OdtRimegepant Sulfate | 88 | $124,235 |
| Emgality PenGalcanezumab-Gnlm | 56 | $40,926 |
| BriviactBrivaracetam | 22 | $33,995 |
| UbrelvyUbrogepant | 25 | $28,998 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $25,471 |
| RytaryCarbidopa/Levodopa | 13 | $22,286 |
| QuliptaAtogepant | 15 | $16,177 |
| Topiramate ErTopiramate | 30 | $15,050 |
| XcopriCenobamate | 14 | $14,768 |
| NeuproRotigotine | 11 | $13,268 |
| Emgality SyringeGalcanezumab-Gnlm | 19 | $13,231 |
| Ajovy SyringeFremanezumab-Vfrm | 16 | $12,984 |
| Tegretol XrCarbamazepine | 14 | $6,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $17 | $513,68212 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $148 | $148,71627 claims |
| PfizerNurtec Odt | $147 | $124,23588 claims |
| UCB, Inc.Briviact, Neupro | $182 | $47,26333 claims |
| AbbVieUbrelvy, Qulipta | $1,636 | $45,17640 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $87 | $22,91125 claims |
| SK Life Science, Inc.Xcopri | $263 | $14,76814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 702 neurology providers in Ohio.
Other neurology in Chillicothe
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
- Aaron BosterColumbus$6.3M
- Ryan DrakeCanton$5.5M
- Aram ZabetiCincinnati$5.3M
- Mark StillmanIndependence$4.6M
- Deren HuangNewark$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.